OncoMatch/Clinical Trials/NCT05694312
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Is NCT05694312 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Ibrutinib 420 mg for autoimmune hemolytic anemia.
Treatment: Ibrutinib 420 mg — This is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Chronic Lymphocytic Leukemia
Prior therapy
Must have received: corticosteroid — AIHA
relapsed after previous treatment with corticosteroids (with or without rituximab), or ... steroid-resistant ... or ... steroid-dependent
Cannot have received: BTK inhibitor (ibrutinib)
Previous exposure to ibrutinib as CLL-directed therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05694312 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BTK inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages